Document is current
Any future updates will be listed below
-
Authors
Diokmetzidou, Antigoni https://orcid.org/0000-0003-1644-8937
Maracani, Aurora https://orcid.org/0009-0005-8128-6462
Pellattiero, Anna https://orcid.org/0000-0002-9793-3493
Cardenas-Rodriguez, Mauricio
Rivière, Erwan A.
Scorrano, Luca https://orcid.org/0000-0002-8515-8928
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG19991, IG27307, fellowship)
Fondazione Umberto Veronesi (NA)
EC | Horizon 2020 Framework Programme (MSCA IEF-891550)
- License Information
-
More Information
Article History
Received: 10 March 2025
Revised: 18 June 2025
Accepted: 9 July 2025
First Online: 21 July 2025
Competing interests
: LS and AP are inventors in the PCT/EP2019/068846 on MYLS22 and Opitor-0 as anticancer drugs. All other authors declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations applicable in Italy. The research reported here does not include studies on vertebrates, or patients and did not require ethical committees approval nor informed consent.
